Rebuild Aging Joints!

15404 Views
Was this article interesting to you?

Scientific Sources

What is UC-II® and how does it work?

UC-II® (undenatured type II collagen) is a patented supplement derived from chicken breast cartilage that induces oral tolerance to joint collagen. By presenting native collagen to T-cells in intestinal Peyer's patches, it 'teaches' the immune system to stop attacking joint cartilage, reducing inflammation by up to 88% in clinical studies (p<0.001).

How effective is UC-II® compared to glucosamine and chondroitin?

Clinical trials show UC-II® reduces WOMAC pain scores by 33% vs 14% for glucosamine/chondroitin after 90 days (p=0.036). VAS pain scores improved 40% with UC-II® vs 15% with glucosamine/chondroitin. Additionally, 89% of glucosamine users needed rescue medication vs only 33% of UC-II® users.

What is the recommended dosage of UC-II®?

The clinically studied dose is 40mg daily (providing 10mg of undenatured type II collagen). Studies used two 20mg capsules taken once daily. This dosage showed significant improvements in joint function within 30 days, with progressive benefits continuing through 90-150 days.

Is UC-II® safe for long-term use?

Yes. Clinical trials including 274 rheumatoid arthritis patients and 52 osteoarthritis patients reported no serious adverse events. Studies lasting up to 3 months showed excellent safety profiles. The supplement is well-tolerated and can be combined with glucosamine and chondroitin for enhanced joint support.

Can UC-II® help with rheumatoid arthritis as well as osteoarthritis?

Yes, UC-II® is effective for both conditions. In rheumatoid arthritis studies, 14% of patients achieved complete remission after 3 months. For juvenile rheumatoid arthritis, 8 of 10 patients responded with 61% reduction in swollen joints and 54% reduction in tender joints.

Clinical Benefits & Efficacy Data

  • Reduces joint pain by 33% (WOMAC scale) and 40% (VAS scale) after 90 days vs 14-15% with glucosamine/chondroitin (p=0.036)
  • Decreases swollen joints by 61% and tender joints by 54% in rheumatoid arthritis patients
  • Achieves 14% complete remission rate in active rheumatoid arthritis (274-patient trial)
  • Reduces rescue medication use by 63% (33% vs 89% in glucosamine group)
  • Shows superior efficacy with just 40mg daily vs 1,500mg glucosamine + 1,200mg chondroitin
  • Provides continuous improvement through 150 days with sustained oral tolerance mechanism
  1. Baseline: Document WOMAC/VAS scores
  2. Dosing: 40mg daily (two 20mg capsules), empty stomach
  3. 30-Day: Re-assess pain, medication use
  4. 90-Day: Expect 30-40% pain reduction
  5. Long-term: Continue 40mg daily indefinitely
  • Osteoarthritis (ICD-10: M19.90)
  • Rheumatoid arthritis (ICD-10: M06.9)
  • Knee arthritis (ICD-10: M17.9)
  • Hip arthritis (ICD-10: M16.9)
  • Joint pain (ICD-10: M25.50)
  • Chicken/poultry allergies
  • Pregnant/nursing women
  • High-dose immunosuppressants without supervision

Clinical Evidence & Study Results

UC-II® vs Glucosamine/Chondroitin - Randomized Trial

Design: Double-blind trial, n=52 knee osteoarthritis patients, 90 days. UC-II® 40mg/day vs glucosamine 1,500mg + chondroitin 1,200mg.

Results: WOMAC pain scores reduced 33% with UC-II® vs 14% with glucosamine/chondroitin (p=0.036). VAS pain improved 40% vs 15% (p<0.05). Rescue medication needed by 33% UC-II® users vs 89% glucosamine users (p<0.001).

Conclusion: UC-II® demonstrated superior efficacy at 67.5-fold lower dose than glucosamine/chondroitin combination.

Citation: Crowley DC et al. Int J Med Sci. 2009;6(6):312-21

Oral Type II Collagen in Rheumatoid Arthritis

Design: Randomized, placebo-controlled trial, n=60 active RA patients, 3 months.

Results: 14% achieved complete disease remission (unprecedented for nutritional intervention). Significant decreases in swollen and tender joint counts vs placebo (p<0.05). For juvenile RA: 80% response rate with 61% reduction in swollen joints, 54% reduction in tender joints.

Conclusion: First demonstration of oral tolerance induction in human autoimmune disease.

Citation: Barnett ML et al. Science. 1993;261(5129):1727-30